Literature DB >> 3515931

Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.

C J White, W A Phillips, L A Abrahams, T D Watson, P T Singleton.   

Abstract

To compare the effects of the calcium channel antagonist, nifedipine, with that of placebo, a randomized double-blind crossover study was performed in 11 patients with moderate to severe Raynaud's phenomenon. Digital skin temperature recovery time was measured after immersing the patient's hand in ice water for 20 seconds. Patients were randomly assigned to receiving either nifedipine or placebo for one week, followed by the crossover phase. Skin temperature recovery time was also measured in 21 normal volunteers. The mean time to recovery for patients taking nifedipine was 28.5 +/- 20.8 minutes versus 44.9 +/- 18.9 minutes for patients receiving placebo (p less than 0.05 by analysis of variance with repeated measures). The mean time to recovery for the normal volunteers was 11.3 +/- 7.2 minutes versus 40.2 +/- 19.9 minutes for the patients (p less than 0.01 by the Student t test). Nine of the 11 patients noted improvement of symptoms during treatment with nifedipine. It is concluded that nifedipine is an effective, well-tolerated treatment for Raynaud's phenomenon.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515931     DOI: 10.1016/0002-9343(86)90817-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.

Authors:  D O'Reilly; L Taylor; K el-Hadidy; M I Jayson
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 2.  Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Authors:  K J Tietze; M L Schwartz; P H Vlasses
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 3.  Thrombolytic treatment and new calcium antagonists.

Authors:  J Feely; T Pringle; D Maclean
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-05

4.  Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Authors:  Soumya Chatterjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

5.  Nifedipine and alpha-adrenoceptor function in human finger skin vessels.

Authors:  L E Lindblad; L Ekenvall; B M Etzell
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 7.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.